β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

Nature Medicine

Volumn 9, Issue 10, 2003, Pages 1300-1305

  Perez, Jeanne Mialet ^a   Rathz, Deborah A ^a   Petrashevskaya, Natalia N ^a   Hahn, Harvey S ^a   Wagoner, Lynne E ^a   Schwartz, Arnold ^a   Dorn II, Gerald W ^a   Liggett, Stephen B ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ARGININE; BETA 1 ADRENERGIC RECEPTOR; CALCIUM; CARVEDILOL; CATECHOLAMINE; GLYCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL GENETICS; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE EXPRESSION; GENETIC POLYMORPHISM; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HOMOZYGOSITY; HYPERTROPHY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ARGININE; CARDIAC OUTPUT, LOW; ECHOCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; GLYCINE; HUMANS; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1;

ANIMALIA;

EID: 0142073817     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm930     Document Type: Article

References (29)

1. Givertz, M.M. Underlying causes and survival in patients with heart failure. N. Engl. J. Med. 342, 1120-1122 (2000).
2. van Campen, L.C., Visser, F.C. & Visser, C.A. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J. Cardiovasc. Pharmacol. 32 (suppl. 1), 831-835 (1998).
3. Franz, W.-M., Müller, O.J. & Katus, H.A. Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358, 1627-1637 (2001).
4. Engelhardt, S., Hein, L., Wiesmann, F. & Lohse, M.J. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. USA 96, 7059-7064 (1999).
5. Liggett, S.B. β-adrenergic receptors in the failing heart: the good, the bad, and the unknown. J. Clin. Invest. 107, 947-948 (2001).
6. 1-adrenergic receptor. J. Biol. Chem. 274, 12670-12674 (1999).
7. 1-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum. Mutat. 14, 271-271 (1999).
8. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739-745 (2000).
9. 2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142 (2002).
10. 1-adrenergic receptor predict exercise capacity in heart failure. Am. Heart J. 144, 840-846 (2002).
11. 1-adrenergic receptor gene and hypertension. Circulation 104, 187-190 (2001).
12. αq overexpression induces cardiac contractile failure in mice. Proc. Natl. Acad. Sci. USA 94, 8121-8126 (1997).
13. 2-adrenergic receptor overexpression in mouse hearts. Circulation 101, 1707-1714 (2000)
14. Bristow, M.R. et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307, 205-211 (1982).
15. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol. Pharmacol. 35, 295-303 (1988).
16. 1-adrenergic receptor: role of internalization, degradation, and mRNA destabilization. Biochem. 41, 8019-8030 (2002).
17. αq-mediated cardiac hypertrophy and ventricular dysfunction. Mol. Pharmacol. 57, 278-287 (2000).
18. Bohm, M. et al. Desensitization of adenylate cyclase and increase of Gi alpha in cardiac hypertrophy due to acquired hypertension. Hypertension 20, 103-112 (1992).
19. Ungerer, M., Bohm, M., Elce, J.S., Erdmann, E. & Lohse, M.J. Altered expression of beta-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87, 454-463 (1993).
20. Bohm, M. et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82, 1249-1265 (1990).
21. iα-2 in human end-stage heart failure. Circ. Res. 70, 688-696 (1992).
22. Packer, M. et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106, 2164-2166 (2002).
23. 1-receptor downregulation in heart failure. Circ. Res. 59, 297-309 (1986).
24. 2-adrenergic receptor signaling J. Biol Chem. 278, 10784-10789 (2003).
25. Yussman, M.G. et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat. Med. 8, 725-730 (2002).
26. 2+]i restores uncoupled beta-adrenergic signaling in isolated perfused transgenic mouse hearts. Circ. Res. 88, 9-11 (2001).
27. Tepe, N.M et al. Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte β-adrenergic signalling. Biochemistry 38, 16706-16713 (1999).
28. Small, K.M., Rathz, D.A. & Liggett, S.B. Identification of adrenergic receptor polymorphisms. Methods Enzymol. 343, 459-475 (2002).
29. 2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ. Res. 86, 834-840 (2000).